Inclusion Criteria:  Male or female patients aged 18-70 years old; Never treated for hypertension or stopped using antihypertensive drugs for at least 2 weeks; In the two screenings,the clinical systolic BP should be in the range of 140-159 mmHg, the diastolic BP < 100 mmHg; The average 24-hour systolic BP ≥130mmHg, daytime systolic BP ≥ 135 mmHg, and nighttime systolic BP ≥ 120 mmHg; The average of bilateral brachial-ankle pulse wave velocity ≥14m/s; Be willing to participate in the trial, sign the informed consent form, and be able to visit doctors by himself or herself.  Exclusion Criteria:  Secondary hypertension; Concomitant obstructive sleep apnea (STOP-BANG score ≥ 5), insomnia, Parkinson's syndrome, or nocturnal polyuria and other diseases that affect nighttime BP; Need to work at night; Ambulatory BP monitoring was invalid (<70% valid readings, or <20 daytime readings or <7 nighttime readings); Concomitant diseases that need taking medications influencing BP; Coronary heart disease, myocardial infarction or stroke within recent 6 months; Atrial fibrillation or frequent arrhythmia; Abnormal liver function exemplified as an increased alanine transaminase (ALT), aspartate transaminase (AST), total bilirubin (TBL) over the double of the upper limit of normal range; abnormal renal function exemplified as a serum creatinine ≥176 µmol/L; and plasma potassium ≥5.5 mmol/L or ≤3.5mmol/L; Pregnant or lactating women; Contraindications of angiotensin II receptor blocker or calcium channel blocker; Other concomitant diseases which are considered not suitable to participate in the trial, such as thyroid diseases, acute infectious diseases, chronic mental diseases, tumor, etc.